Insulet Corp at Raymond James Institutional Investors Conference Transcript
All right. Good morning. I think we'll get started. Welcome to the 41st Annual Raymond James Institutional Investors Conference. My name is Jayson Bedford. I'm one of the medical device analyst here at Ray J. It's our privilege to have with us the senior management team from Insulet. They've been a loyal participant in this conference for many years.
With us, we have Head of Investor Relations and Corporate Communications, Deb Gordon; CFO, Wayde McMillan; and the CEO, Shacey Petrovic. So I will hand it off to Shacey, and we'll have the breakout downstairs in, I think, Amarante 5.
Thanks, Jason. So I might be double mic-ed here. So hopefully, I'm okay. But it's great to be with you all this morning to share a bit about Insulet Corporation. Our mission at Insulet is to improve the lives of people living with diabetes. And we do that through our novel Omnipod
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |